Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has received an average rating of "Moderate Buy" from the eleven research firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, seven have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $15.60.

YMAB has been the topic of a number of recent research reports. Bank of America cut shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price target on the stock. in a research report on Tuesday, April 22nd. HC Wainwright cut their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Oppenheimer decreased their target price on shares of Y-mAbs Therapeutics from $20.00 to $15.00 and set an "outperform" rating on the stock in a research report on Thursday, May 29th. Truist Financial lowered their price target on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Finally, Wedbush restated an "outperform" rating and set a $18.00 price target (down from $21.00) on shares of Y-mAbs Therapeutics in a research report on Wednesday, May 28th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of YMAB. Rhumbline Advisers grew its position in shares of Y-mAbs Therapeutics by 4.8% in the 1st quarter. Rhumbline Advisers now owns 53,909 shares of the company's stock worth $239,000 after buying an additional 2,457 shares during the last quarter. Strs Ohio purchased a new stake in Y-mAbs Therapeutics in the first quarter worth $192,000. Acorn Capital Advisors LLC boosted its holdings in Y-mAbs Therapeutics by 13.1% in the first quarter. Acorn Capital Advisors LLC now owns 3,235,387 shares of the company's stock valued at $14,333,000 after acquiring an additional 373,562 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in Y-mAbs Therapeutics by 58.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 237,511 shares of the company's stock valued at $1,052,000 after acquiring an additional 87,830 shares in the last quarter. Finally, AQR Capital Management LLC increased its position in Y-mAbs Therapeutics by 869.3% during the 1st quarter. AQR Capital Management LLC now owns 164,788 shares of the company's stock valued at $730,000 after purchasing an additional 147,788 shares during the period. Hedge funds and other institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Stock Up 1.1%

NASDAQ:YMAB traded up $0.05 during midday trading on Friday, hitting $4.31. The company had a trading volume of 81,293 shares, compared to its average volume of 298,167. Y-mAbs Therapeutics has a 52-week low of $3.55 and a 52-week high of $16.11. The stock's fifty day moving average price is $4.47 and its 200-day moving average price is $5.39. The company has a market capitalization of $194.93 million, a PE ratio of -6.73 and a beta of 0.51.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative return on equity of 30.59% and a negative net margin of 31.84%. The firm had revenue of $20.90 million during the quarter, compared to analyst estimates of $19.97 million. As a group, research analysts forecast that Y-mAbs Therapeutics will post -0.65 earnings per share for the current year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.